This phase 1b/2, multicenter, open-label study evaluated ibrutinib plus durvalumab in relapsed/refractory follicular lymphoma (FL) or diffuse large B-cell lymphoma (DLBCL).
| INTRODUCTION
Diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL) are the most common subtypes of non-Hodgkin lymphoma in adults. [1] [2] [3] [4] Although most patients respond to first-line chemoimmunotherapy, a substantial proportion of patients with DLBCL and most patients with FL will eventually relapse or have refractory disease. [1] [2] [3] [4] [5] The treatment of relapsed/refractory DLBCL and FL remains challenging, with a minority of patients with DLBCL achieving durable remission and patients with FL experiencing decreased duration of remission with successive therapies. [1] [2] [3] [4] [5] Effective, well-tolerated therapy for relapsed/refractory DLBCL and FL remains an unmet need.
Ibrutinib, a first-in-class, once-daily inhibitor of Bruton's tyrosine kinase (BTK), is approved in the United States, Europe, and other countries for the treatment of various B-cell malignancies. 6, 7 In addition to BTK, ibrutinib has also been shown to inhibit interleukin 2-inducible kinase, resulting in suppression of Th2 cells and potentiation of Th1-mediated immunity. 8 Although ibrutinib has demonstrated clinically meaningful efficacy against many B-cell malignancies, the ORR to ibrutinib alone for patients with relapsed/refractory FL is approximately 21%-38% among current studies, and the ORR for patients with relapsed/refractory DLBCL receiving single-agent ibrutinib is 28%, motivating the investigation of combination approaches to improve response. [9] [10] [11] Programmed death (PD)-1, an inhibitory receptor expressed by activated T cells, limits autoimmunity by suppressing T cell-mediated immune responses following engagement by its ligands, PD-L1 or PD-L2. 12 Tumors frequently exploit the PD-1 pathway to evade immune surveillance via upregulation of PD-1 and/or PD-L1 expression on tumor cells and tumorassociated immune cells. 13 Gene amplification of the PD-1 ligands and overexpression of PD-L1 on tumor cells and tumor-associated macrophages is present in certain subsets of patients with DLBCL, 14, 15 and PD-L1 expression is associated with poorer survival after standard therapy. 16 High PD-1 expression on CD4+ tumor-infiltrating lymphocytes has been observed in FL. [17] [18] [19] Durvalumab is an anti-PD-L1 antibody that restores antitumor immune responses. 20 Other PD-1/PD-L1-targeted agents have demonstrated antitumor activity in patients with DLBCL or FL. [21] [22] [23] [24] Notably, data from murine lymphoma models suggest that ibrutinib combined with an anti-PD-L1 antibody may have synergistic antitumor activity. 25 Together, the immune-modulating properties of ibrutinib, PD-1/PD-L1 expression observed in patients with DLBCL and FL, and preclinical data suggesting synergy between the agents provide a strong rationale for investigating the combination of ibrutinib with PD-1/PD-L1 blockade in FL and DLBCL.
We therefore performed a phase 1b/2 study to evaluate the safety and antitumor activity of the combination of ibrutinib and durvalumab in patients with relapsed/refractory DLBCL or FL.
| METHODS

| Patients
Key eligibility criteria included age ≥18 years; pathologically confirmed DLBCL, with subtype identified via gene expression or immunohistochemistry tests, or FL (grade 1, 2, or 3A) according to World Health Organization criteria; relapsed/refractory disease to at least one line of therapy; measurable disease (≥1 lesion >1.5 cm in longest dimension); adequate hematological function independent of transfusion and growth factor support; adequate hepatic and renal function; prothrombin time <1.5 times the upper limit of normal (ULN) and activated partial thromboplastin time <1.5 times ULN; and Eastern Cooperative Oncology Group performance status of 0 or 1. In the phase 2 portion of the study within the DLBCL cohort, patients with germinal center B-cell (GCB) and non-GCB subtypes were to be enrolled in a 1:1 ratio.
| Study design, treatment, and oversight
This was an open-label, multicenter phase 1b/2 study conducted at 12 centers in the United States from May 2015 to February 2018.
The phase 1b portion of the study employed a 6 + 3 de-escalation design to determine the recommended phase 2 dose of ibrutinib in combination with durvalumab, with starting doses of ibrutinib 560 mg and durvalumab 10 mg/kg in cohort 1. The first patient in each dose cohort served as a sentinel patient who was observed for a period of ≥3 days to monitor for any unexpected acute or overlapping toxicities before dosing of the next patient. If two of the first six patients experienced a dose-limiting toxicity (DLT) during cycle 1, an additional three patients were to be enrolled. If ≤1 of six or ≤2 of nine patients experienced a DLT, the dose level was to be defined as the recommended phase 2 dose. If ≥2 of six or ≥3 of nine DLTs were observed, dose de-escalation cohorts (ibrutinib to 420 mg and/or durvalumab to 3 mg/kg) were available to be opened. In the phase 2 portion of the study, patients were treated at the recommended phase 2 dose as determined in phase 1b. In all cohorts, ibrutinib was administered orally once daily for up to 3 years in combination with durvalumab given intravenously on days 1 and 15 of each 28-day cycle for up to 12 cycles in the absence of progressive disease (PD) or unacceptable toxicity.
This study was conducted according to principles of the Declaration of Helsinki and the International Conference on Harmonisation Guidelines for Good Clinical Practice, The study was approved by the institutional review boards, research ethics boards, or independent ethics committees of participating institutions. All patients provided written informed consent. This study was registered with ClinicalTrials.gov, number NCT02401048.
| Outcomes and assessments
The primary endpoints of the phase 1b portion of the study were to determine the recommended phase 2 dose of ibrutinib in combination with durvalumab as well as safety and tolerability; secondary endpoints included overall response rate (ORR) and duration of response.
The primary endpoint of the phase 2 portion of the study was the ORR; secondary endpoints included duration of response, progression-free survival (PFS), overall survival (OS), safety, and tolerability.
Response evaluations were performed every three cycles until cycle 12 and every six cycles thereafter. Response was assessed by the investigator according to revised criteria for malignant lymphoma described by the International Working Group for non-Hodgkin Lymphoma. 26 Adverse events (AEs) were coded using the Medical Dictionary for Regulatory Activities (version 20.0) and graded according to the National Cancer Institute Common Terminology Criteria for AEs (CTCAE), version 4.03. Treatment-emergent adverse events (TEAEs) were defined as (1) any AE occurring after the start of study treatment and within 30 days of the last dose of ibrutinib or within 90 days after the last dose of durvalumab, (2) any study drug-related AE regardless of start date, or (3) any AE present at baseline that worsens in severity of frequency after the start of study treatment or is considered by the investigator to be study drug-related. Treatment-related DLTs followed guidelines provided in the CTCAE (version 4.03) and were defined as (1) any grade 3 or higher nonhematologic AE or (2) clinically relevant hematologic AE. Tumor mutation burden was limited to mutations that resulted in changes in amino acids and was evaluated for correlations in patients with complete response (CR), in nonevaluable (nonresponsive) patients, or in patients with PD using a Wilcoxon rank-sum test. The pharmacodynamics of durvalumab were assessed through measurement of the reduction in levels of free soluble PD-L1 in serum using an enzyme-linked immunosorbent assay.
| Biomarker analysis
| Statistical analysis
Efficacy and safety were evaluated in all patients who received ≥1 dose of any study treatment. ORR was evaluated as the proportion of patients achieving a best overall response of CR or partial response with two-sided 95% confidence intervals (CIs) based on exact binomial distribution (Clopper-Pearson interval). Time to event endpoints were estimated using the Kaplan-Meier method. Safety and tolerability were analyzed using descriptive summaries.
The statistical design for both the FL and DLBCL cohorts in phase 2, including number of patients and responders, follows the statistical framework of Simon's two-stage design. 29 To ensure adequate statistical power to determine a difference in ORR compared with singleagent ibrutinib for the phase 2 portion of the study, a maximum of 39 FL patients and 34 DLBCL patients (at a 1:1 ratio for GCB and non-GCB subtypes) were enrolled. Interim analysis was planned for the first 19 response-evaluable patients in the FL cohort and for the first nine response-evaluable patients in the DLBCL cohort. The response-evaluable population was defined as all patients who received ≥1 dose of any study treatment and provided ≥1 postbaseline response assessment. Cohort discontinuation was to be considered if there were ≤6 of 19 responders in the FL cohort or ≤1 of nine responders in the DLBCL cohort. However, assessment of biomarkers or tumor measurements could support continued enrollment. and white (90%) ( Table 1 ). The median time from initial diagnosis to the first dose of study treatment was 26.1 months (range: 6.0-362.5).
Most patients (85%) had received ≥2 prior treatment regimens (median: 2 regimens [range: 1-7]) and 52% had disease that was refractory to the last prior regimen ( Table 1) .
Sixty-one patients received ≥1 dose of ibrutinib and 58 patients received ≥1 dose of durvalumab; one enrolled patient did not receive any study treatment. The most common reason for discontinuation of study treatment was PD (Table S1) No DLTs were observed in the phase 1b portion of the study. Therefore, the starting dose level of ibrutinib 560 mg once daily in combination with durvalumab 10 mg/kg every 2 weeks was defined as the recommended phase 2 dose level. These doses are the highest approved single-agent dose for each study treatment.
| Best overall response
Among 61 patients who were treated, 15 patients had an objective response (25%; 95% CI, 15-37). ORRs were 26% (7/27 patients; 95% CI, 11-46) in FL patients, 13% (2/16 patients; 95% CI, 2-38) in patients with GCB DLBCL, and 38% (6/16 patients; 95% CI, in patients with non-GCB DLBCL ( Figure 1A ). CR was observed in one (4%) FL patient, one (6%) GCB DLBCL patient, and five (31%) non-GCB DLBCL patients. Partial response was observed in six (22%) FL patients, one (6%) GCB DLBCL patient, and one (6%) non-GCB DLBCL patient.
Among all patients with a best response of CR or partial response, median duration of response was 11.3 months (95% CI, 5.5-not eval- ( Figure S1 ). 
| PFS and OS
| Biomarkers
Overall baseline tumor mutation load based on a targeted panel con- and CANT1 genes were correlated with increased tumor shrinkage (n = 11) ( Figure S2 ). Additionally, the P21R single nucleotide polymorphism (SNP) in the TNFRSF13C gene was correlated with clinical progression in non-GCB DLBCL patients (n = 7).
For all 41 patients with evaluable data, serum PD-L1 was suppressed to below the limit of quantitation starting within 10 minutes of the first dose of durvalumab and continuing throughout the dosing interval, 
| Safety
Among the 61 patients who received ≥1 dose of study medication, the median duration of exposure to ibrutinib was 3.8 months (range: 0.1-23.2) and median duration of exposure to durvalumab was 3.0 months (range: 0.0-10.6). The most common TEAEs were generally grade 1/2 ( Table 2 ). Atrial fibrillation, arthralgia, and anemia of any grade each occurred in 10% of all patients. Grade 3/4 TEAEs were reported in 34 (56%) patients; the most frequent (≥5%) grade 3/4
TEAEs were neutropenia (n = 13, 21%), dyspnea (n = 6, 10%), fatigue (n = 5, 8%), atrial fibrillation (n = 4, 7%), peripheral edema (n = 4, 7%), and rash maculopapular (n = 4, 7%) ( 
| DISCUSSION
Ibrutinib has been shown to suppress regulatory T cells, increase activation of cytotoxic T cells, and enhance proinflammatory cytokine secretion, 9, 30 all of which might be expected to provide a more favorable tumor microenvironment for response to PD-1/PD-L1-targeted therapies. Despite this strong rationale for the combination of ibrutinib with PD-1/PD-L1-targeted therapy and preclinical evidence in murine lymphoma models for synergistic antitumor activity with ibrutinib plus durvalumab, 25 our phase 1b/2 study of ibrutinib 560 mg once daily with durvalumab 10 mg/kg every 2 weeks met the early efficacy stopping rule. This suggests that the antitumor activity of the combination was similar to what would be expected with single-agent ibrutinib therapy in patients with relapsed/refractory FL and DLBCL.
In patients with relapsed/refractory FL, the ORR of 26% with the combination of ibrutinib plus durvalumab was similar to the ORR of 21% observed with single-agent ibrutinib in patients with relapsed/refractory FL in the phase 2 DAWN study 9 and was slightly lower than the ORR of 38% observed with single-agent ibrutinib in a phase 2 consortium in patients with relapsed/refractory FL. 10 Although the ORR of 26% with ibrutinib plus durvalumab was lower than the previously observed response rate in a phase 1 study of single-agent nivolumab in patients with relapsed/refractory FL (40%), 23 the activated B-cell subtype and 5% in those with the GCB subtype. 32 The differential response rates between these subtypes is probably explained by chronic active B-cell receptor signaling, which activates the NF-ĸB pathway through BTK in non-GCB tumors but not in GCB tumors. 33 DLBCL of the non-GCB subtype might also be expected to benefit to a greater extent from PD-1/PD-L1-targeted therapy, as high PD-L1 expression is only observed in non-GCB subtypes. 14, 15 While single-agent PD-1 blockade has demonstrated antitumor activity in patients with relapsed/refractory DLBCL, cell-of-origin analyses have not been conducted. 21, 23 In addition, despite the promising activity observed in initial studies, a larger phase 2 study of nivolumab in relapsed/refractory DLBCL demonstrated a response rate of only 10% (n = 121). 24 Tumor mutation load was not found to correlate with best response Based on initial studies that suggested promising antitumor activity with PD-1/PD-L1 blockade, we and others undertook studies to evaluate the safety and activity of anti-PD-1/PD-L1-based combinations.
However, subsequent studies of anti-PD-1 monotherapy have demonstrated that the single-agent response rate in FL and DLBCL is 10% or lower (ClinicalTrials.gov, NCT02038946). Unfortunately, despite a strong rationale and promising preclinical data, the combination of ibrutinib and durvalumab demonstrated similar activity to single-agent ibrutinib and was associated with the added toxicity of PD-L1 blockade, although the safety profile of the combination was generally consistent with those known for each individual agent. Thus, this combination does not warrant further study in FL or DLBCL. As PD-1/PD-L1 combinations continue to be evaluated in patients with non-Hodgkin lymphoma, it will be critical to understand the biological basis for response to those agents in order to identify target populations for further study. ORCID Alex F. Herrera https://orcid.org/0000-0002-9665-7415
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